Enoxaparin and percutaneous coronary intervention: A Canadian perspective

Canadian Journal of Cardiology

Volumn 21, Issue 6, 2005, Pages 501-507

  Fitchett, David ^a   Welsh, Robert ^b   Langer, Anatoly ^a   Goodman, Shaun ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acute coronary syndromes; Enoxaparin; Percutaneous coronary intervention

Indexed keywords

ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PROTAMINE;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CANADA; CLINICAL PROTOCOL; DOSE RESPONSE; HEALTH SURVEY; HEART CATHETERIZATION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; QUESTIONNAIRE; RISK ASSESSMENT; THROMBOSIS;

ANGINA, UNSTABLE; ANGIOPLASTY, BALLOON; ANTICOAGULANTS; ATTITUDE OF HEALTH PERSONNEL; CANADA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; HUMANS; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; QUESTIONNAIRES;

EID: 20444463114     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
2. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-8.
3. Antman EM, McCabe CH, Gurfinkel EP, et al. Treatment benefit of enoxaparin in unstable angina/non-Q wave myocardial infarction is maintained at one year follow-up in TIMI 11B. Circulation 1999;100(Suppl I):I-497. (Abst)
4. Cohen M, Demers C, Gurfinkel EP, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: The ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 1998;82:19L-24L.
5. Braunwald E, Antman EM, Beasley JW, et al; American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-74.
6. Goodman SG, Fitchett D, Tan M, et al, for the Canadian Acute Coronary Syndromes Registry Group. Management of acute coronary syndromes (ACS) in Canada: Anti-platelet/thrombotic therapy in the first 24 hours. Can J Cardiol 2001;17(Suppl C):228C. (Abst)
7. Goodman SG, Tan M, Spindler C, et al, for the Canadian Acute Coronary Syndromes Registry Group. Coronary angiography and revascularization in acute coronary syndromes (ACS): What the Canadian ACS Registry reveals about 'real world' management during index hospitalization. Can J Cardiol 2001;17(Suppl C):228C. (Abst)
8. Ferguson JJ, Antman EM, Bates ER, et al; NICE-3 Investigators. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: Final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 2003;146:628-34.
9. Young JJ, Kereiakes DJ, Grines CL; National Investigators Collaborating on Enoxaparin Investigators. Low-molecular-weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials. J Invasive Cardiol 2000;12(Suppl E):E14-8.
10. Argenti D, Hoppensteadt D, Heald D, Jensen B, Fareed J. Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. Am J Ther 2003;10:241-6.
11. Aslam MS, Sundberg S, Sabri MN, Cooke D, Lakier JB. Pharmacokinetics of intravenous/Subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv 2002;57:187-90.
12. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-63.
13. Levine GN, Ferguson JJ III. Low-molecular-weight heparin during percutaneous coronary interventions: Rationale, results, and recommendations. Catheter Cardiovasc Interv 2003;60:185-93.
14. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: An expert consensus. Am Heart J 2002;144:615-24.
15. Moliterno DJ, Hermiller JB, Kereiakes DJ, et al; ELECT Investigators. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol 2003;42:1132-9.
16. Ferguson JJ, Califf RM, Antman EM, et al; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
17. Cohen M, Theroux P, Borzak S, et al; ACUTE II Investigators. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 2002;144:470-7.
18. Goodman SG, Fitchett D, Armstrong WP, Tan M, Langer A; Integritin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-44.
19. Blazing MA, de Lemos JA, White HD, et al; A to Z Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA 2004;292:55-64. (Erratum in 2004;292.1178)
20. Fox KA, Poole-Wilson PA, Henderson RA, et al; Randomized Intervention Trial of unstable Angina Investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: The British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002;360:743-51.
21. Collet JP, Montalescot G, Golmard JL, et al. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes. Am Heart J 2004;147:655-61.
22. Singh KP, Roe MT, Chen AY, et al. Improved outcomes with low-molecular weight heparin for patients receiving glycoprotein IIb/IIIa antagonists for acute coronary syndromes: Results from the CRUSADE Initiative. Circulation 2003;108(Suppl IV):IV-579.